Glenmark Life Sciences Ltd. IPO
Glenmark Life Sciences Ltd.
IPO Listing Details
Listed On
BSE & NSE
Listed On
Issue Price
₹720
Issue Price
Listing Price
₹751
Listing Price
Listing Gains
+₹31.10 (+4.32%)
Listing Gains
IPO Details
Bidding Dates
27 Jul - 29 Jul '21
Bidding Dates
Min. Investment
₹13,900
Min. Investment
Lot Size
20.00
Lot Size
Price Range
₹695 - ₹720
Price Range
Issue Size
1,461 Cr
Issue Size
Subscription Rate
- Retail Individual Investor14.63x
- Non-Institutional Investor122.54x
- Qualified Institutional Buyers36.97x
- Employees0.00x
About Company
Glenmark Life Sciences is an Indian producer of drugs that supplies APIs to a number of pharmaceutical companies globally. It is associated with 16 of the largest 20 generic drug companies worldwide. In all, it supplies materials to 540 pharma companies all over the world. The company works to positively impact all aspects of the value chain and support customers in regions such as North America, Europe, Japan, Latin America and ROW with product identification and development apart from R&D, manufacturing and delivery.
Glenmark Life Sciences Ltd. IPO Latest News and Subscription Status Today (Live)
During the Glenmark Life Sciences IPO, its shares were listed at a 4 per cent premium over the issue price of Rs 720 per share. The company raised Rs 1,060 crore through the fresh issue and Rs 453.60 crore from offer for sale. It was subscribed 44.17 times. As the 30-day lock-in period for investors ended, the stock traded below the IPO issue price of Rs 720.
Why should you invest in Glenmark Life Sciences Ltd. IPO?
Glenmark Life Sciences has accounted for 30-35% of Glenmark Pharma's overall value. Glenmark Pharma itself has been listed on the exchanges for more than 20 years and is widely considered to be delivering strong returns.
The API segment is expected to grow at a CAGR of 8.5% in the next five years. Moreover, Glenmark Life Sciences has a number of blue-chip clients as it is associated with 16 out of the 20 largest generic drug manufacturers.
Glenmark Life Sciences Ltd. IPO - SWOT Analysis
Strengths:
The company has built technically complex and niche molecules in a business characterised by high volumes and low margins, It has more than 30 per cent market share in some of its principal products which combine to contribute 44 per cent to the total business. Its total market size is $142 billion with 403 Drug Master Files (DMFs) and 39 (owned and co-owned) patents.
Weaknesses:
It is routinely subjected to inspections from regulators and any adverse observations could
Opportunities:
There is terrific scope to expand on account of Glenmark Life Sciences' strong cash flow. Its robust R&D infrastructure would ensure that it can improve the quality of products and gain more customers.
Threats:
In the event that the company fails to make the right predictions for the demand of its products, it could become difficult to manage inventory.How to apply for Glenmark Life Sciences Ltd. IPO?
You can apply for the Glenmark Life Sciences Ltd. IPO in these ways:
UPI
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.
Demat Account
1. If you are an Existing TradeSmart demat account holder and wish to apply for an Glenmark Life Sciences Ltd. click here.
2. If you don't have a TradeSmart Account? Sign up.
